



## Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

April 20, 2023

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, "Ikena"), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in one-on-one investor meetings at the Stifel 2023 Virtual Targeted Oncology Days, taking place April 25-26, 2023.

Ikena's Chief Executive Officer, Mark Manfredi, Ph.D., will present a corporate overview on Tuesday, April 25 highlighting advancements across the company's pipeline of targeted oncology programs, including recent preclinical data shared at AACR 2023 Annual Meeting around the differentiation profile of IK-930, the company's novel Hippo pathway inhibitor that selectively binds and inhibits TEAD1.

Details are as follows:

**Presenter:** Mark Manfredi, Ph.D., Chief Executive Officer of Ikena Oncology

**Date:** Tuesday, April 25, 2023

**Time:** 2:30 p.m. – 2:55 p.m. ET

**Location:** Virtual

[Webcast Link](#)

The webcast link will stream the presentation and will be archived for 30 days following the end of the conference, accessible above. The presentation webcast can also be accessed by visiting the Investors & Media section of the company's website at [www.ikenaoncology.com](http://www.ikenaoncology.com).

### About Ikena Oncology

Ikena Oncology™ is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a paralog-selective TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's additional research spans other targets in the Hippo pathway as well as the RAS signaling pathway, including developing IK-595, a novel MEK-RAF inhibitor. Additionally, IK-175, an AHR antagonist, is being developed in collaboration with Bristol Myers Squibb. Ikena aims to utilize their depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient. To learn more, visit [www.ikenaoncology.com](http://www.ikenaoncology.com) or follow us on [Twitter](#) and [LinkedIn](#).

### Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding: the timing and advancement of our targeted oncology programs, including the timing of updates; our expectations regarding the therapeutic benefit of our targeted oncology programs; our ability to efficiently discover and develop product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the implementation of our business model, and strategic plans for our business and product candidates. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of our targeted oncology programs; our expectations regarding the therapeutic benefit of our targeted oncology programs; expectations regarding our new executive officer; our ability to efficiently discover and develop product candidates; the implementation of our business model, and strategic plans for our business and product candidates, and other factors discussed in the "Risk Factors" section of Ikena's Form 10-K for the year ended December 31, 2022, which is on file with the SEC, as updated by any subsequent SEC filings. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

### Investor Contact:

Rebecca Cohen

Ikena Oncology

[rcohen@ikenaoncology.com](mailto:rcohen@ikenaoncology.com)

### Media Contact:

Luke Shiplo

LifeSci Communications

[lshiplo@lifescicomms.com](mailto:lshiplo@lifescicomms.com)